Michael Finley

Merck & Co., Inc., Rahway, NJ, USA (United States)

Papers

1

Total Citations

6

H-Index

1

About

Michael Finley is a specialist in assay automation and high-throughput screening, with a focus on advancing the precision and efficiency of early-stage drug discovery. His key research areas include the development of automated platforms for pharmacological characterization, particularly cross-titration and agonist shift experiments. Finley’s major contribution is the creation of a fully automated system that enables robust, unattended execution of these complex assays, significantly reducing manual labor and variability while increasing throughput. His most cited work, "Development of a Platform to Enable Fully Automated Cross-Titration Experiments" (2016), has garnered 6 citations and serves as a foundational reference for laboratories seeking to integrate automation into their hit triage and lead optimization workflows. By streamlining the process of testing compounds at multiple concentrations and performing agonist shift studies, Finley’s innovations help researchers more accurately determine potency, maximal effect, and mechanism of action. His work is particularly valuable for teams transitioning from high-throughput screening to detailed pharmacological profiling, making him a notable contributor to the practical application of automation in modern drug discovery.

Research Focus

Key Achievements

1
H-Index
1
Papers
6
Total Citations
6
Avg Citations/Paper
🏆 Most Cited Paper
Development of a Platform to Enable Fully Automated Cross-Titration Experiments
6 citations · 2016
📈 Most Prolific Year: 2016 (1 Papers)
🤝 Key Collaborators: 8
🏛 Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago